Navigation Links
For Juvenile Arthritis, Pill May Work as Well as Needle
Date:5/31/2012

THURSDAY, May 31 (HealthDay News) -- Taking the arthritis drug methotrexate in pill form was just as effective as receiving it by injection for the long-term treatment of children with juvenile rheumatoid arthritis, a new study has found.

Since both methods also have a similar incidence of side effects, researchers said the findings suggest that children may as well take the medication as a pill instead of having to put up with the discomfort of injections.

They noted, however, that their study looked back at registry information on kids with arthritis. More research -- including controlled clinical trials, the gold standard of research -- is needed before making a treatment recommendation.

The study, published May 30 in the journal Arthritis Care & Research, was funded by drug maker Wyeth BioPharma.

Methotrexate (brand name Rheumatrex) is one of the most common first-line disease-modifying antirheumatic drug treatments for arthritis.

In this study, German researchers compared more than 150 patients who received methotrexate injections and more than 250 patients who took the drug orally. The male and female patients, who had a median age of 10, all received comparable doses.

After six months of treatment, nearly three-quarters of patients -- including 73 percent receiving injections and 72 percent receiving the pill form -- showed a response to the drug. At least one negative side effect was reported in 27 percent of those receiving injections and 22 percent of those on the oral drug.

Eleven percent of patients receiving injections stopped treatment due to negative side effects, compared with 5 percent of those on oral therapy, the researchers noted.

Juvenile rheumatoid arthritis, also called juvenile idiopathic arthritis, affects between 10 and 100 per 100,000 children younger than 16. It is the most common chronic inflammatory disease in children and can lead to severe disability. About 294,000 U.S. children have the disease, according to the American College of Rheumatology.

One expert in the United States agreed that methotrexate seemed to work equally well regardless of how the children received it.

"Methotrexate is one of the disease-modifying agents used to treat arthritis -- it can be taken as a pill or as a subcutaneous [under the skin] injection and pediatric rheumatologists have felt that the parenteral route (injection) has been the most efficacious," said Dr. B. Anne Eberhard, a pediatric rheumatologist at Cohen Children's Medical Center in New Hyde Park, N.Y. However, she added, "this study from Germany suggests otherwise."

Still, while some children did experience "significant improvement in their arthritis" with methotrexate, most patients "did not achieve remission in their illness, which is the ultimate aim in treating children with juvenile idiopathic arthritis," Eberhard noted.

More information

The Nemours Foundation has more about juvenile rheumatoid arthritis.

-- Robert Preidt

SOURCES: B. Anne Eberhard, M.D., pediatric rheumatologist, Cohen Children's Medical Center, New Hyde Park, N.Y.; Arthritis Care & Research, news release, May 30, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Injection of methotrexate not superior to oral therapy in juvenile arthritis treatment
2. Children with juvenile arthritis have higher rates of bacterial infection
3. Social workers should reclaim role in juvenile corrections system, MU researcher says
4. Study identifies factors linked with better medication response for treatment of juvenile arthritis
5. Sonography complements physical exam in identifying juvenile inflammatory arthritis in children
6. Better HIV prevention interventions needed for juvenile offenders
7. New clinical practice guidelines developed for juvenile idiopathic arthritis
8. Doctor Shortage Adds to Pain of Juvenile Arthritis
9. Biologics-naive juvenile idiopathic arthritis patients have elevated risk of cancer
10. Montreal researchers shed light on common juvenile cancer
11. Most states offer HPV vaccinations to girls in juvenile justice system
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
For Juvenile Arthritis, Pill May Work as Well as Needle
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... , ... August 18, 2017 ... ... Quick International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex ... into a definitive agreement to purchase Unitrans International Corporation, a division of ...
(Date:8/18/2017)... ... 18, 2017 , ... As an industry leader, Eppendorf is ... will present the line of epMotion automated liquid handling system. This automated liquid ... everyday pipetting tasks. , Ideal for scientists and lab technicians with no or ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Golseth ... in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide ... , In early June of this year, Christina and her children returned from out ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., a ... , today announced that the company has provided an ... of North Carolina at Chapel Hill and to Qura ... to characterize and quantify HIV reservoir and viral expression ... intervention. The HIV Cure Center is a joint initiative ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
Breaking Medicine Technology: